Edith P. Mitchell - 06 Dec 2023 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: Director
Issuer ticker: CRVS
Reported as of: 06 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Dec 2023, 16:06:11 UTC
Prior SEC filing: 20 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Edith P. Mitchell

Key filing fact

Edith P. Mitchell filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 08 Dec 2023.

Key facts

This page summarizes Edith P. Mitchell's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Dec 2023, 16:06.

Change

Previous filing in this sequence was filed on 20 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 06 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $1.64
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.